UCL Discovery
UCL home » Library Services » Electronic resources » UCL Discovery

Questions EMERGE as Biogen claims aducanumab turnaround

Howard, R; Liu, KY; (2020) Questions EMERGE as Biogen claims aducanumab turnaround. Nature Reviews Neurology , 16 pp. 63-64. 10.1038/s41582-019-0295-9. Green open access

[thumbnail of Howard_Commentary_KLRHKL5.pdf]
Preview
 Text
Howard_Commentary_KLRHKL5.pdf - Accepted Version
Download (640kB) | Preview

Abstract

Trials of aducanumab in Alzheimer disease were previously discontinued following a phase III futility analysis, but Biogen now says that additional data indicate that longer exposure to the higher dose might be effective. The company is seeking FDA approval for the treatment; however, the limited data released do not establish efficacy.

Type: Article
Title: Questions EMERGE as Biogen claims aducanumab turnaround
Location: England
Open access status: An open access version is available from UCL Discovery
DOI: 10.1038/s41582-019-0295-9
Publisher version: https://doi.org/10.1038/s41582-019-0295-9
Language: English
Additional information: This version is the author accepted manuscript. For information on re-use, please refer to the publisher’s terms and conditions.
Keywords: Alzheimer's disease, Clinical trials, Neurodegenerative diseases
UCL classification: UCL
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > Division of Psychiatry
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > Division of Psychiatry > Mental Health of Older People
URI: https://discovery.ucl.ac.uk/id/eprint/10091422
Downloads since deposit
1,617Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item